BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, December 26, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 13, 2014

View Archived Issues

Structure-based development of novel bromodomain and extra-terminal domain inhibitors

Read More

New mechanism of action for small-molecule antidiabetic drugs reported

Read More

Isarna Therapeutics and Santaris Pharma to develop next-generation oligonucleotides

Read More

Insight Genetics given phase II NCI contract for lung cancer resistance test

Read More

Bayer and Peking University establish new research center in Beijing

Read More

XTL Biopharmaceuticals in-licenses hCDR1 for lupus

Read More

BioDefense Therapeutics enrolls first patient in phase III trials of favipiravir

Read More

OxiGene presents results from a phase I trial evaluating OXi-4503 in patients with AML and MDS

Read More

Researchers present phase I results for 225Ac-lintuzumab in older patients with AML

Read More

MedImmune and Immunocore enter agreement to develop cancer therapies

Read More

Polish researchers divulge new amphotericin B derivatives for fungal infections

Read More

DiaMedica begins phase II trial of DM-199

Read More

GlaxoSmithKline presents a novel antibody-drug conjugate for the treatment of multiple myeloma

Read More

University of Massachusetts Medical School to develop PiZ antibody for the Alpha-1 Project

Read More

AC Immune raises funds and initiates trial of vaccine candidate for Alzheimer's disease

Read More

Neurovance reports interim data from phase IIIa pilot study of EB-1020 SR

Read More

FDA grants QIDP and fast track status to amikacin fosfomycin inhalation system

Read More

Sunesis Pharmaceuticals expands hematology pipeline with two kinase inhibitor programs

Read More

Vertex reports first data from study of VX-135 in combination with daclatasvir

Read More

Neurocrine reports 12-week results from phase IIb study of tardive dyskinesia candidate

Read More

PaxVax discloses interim results from phase III study of single-dose oral cholera vaccine candidate

Read More

Avelas Biosciences raises funds to advance real-time cancer visualization technology

Read More

Vanderbilt University patent divulges novel mGlu5 receptor PAMs

Read More

Sunovion researchers prepare and test PDE10A inhibitors

Read More

Sanofi reports development of PIK3C3 inhibitors

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Illustration of tau accumulating in a neuron cell.

    ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

    BioWorld
    ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing